Janssen Collaborates with Arrowhead for the Initiation of REEF-1 P-IIB Study in Patients with Chronic Hepatitis B Infection

 Janssen Collaborates with Arrowhead for the Initiation of REEF-1 P-IIB Study in Patients with Chronic Hepatitis B Infection

Genmab and Janssen Biotech Report Initiation of P-III MMY3021 Study for Darzalex (daratumumab) in Multiple Myeloma

Shots:

  • Janssen to pay ~$25M milestone payments to Arrowhead with the onset of trial and has begun the dosing of patients in REEF-1(NCT03982186) P-IIB study involving assessing of JNJ-3989, JNJ-6379, NA, and/or PBO in 450 patients with chronic hepatitis B virus infection for 48 wks., evaluating its safety and efficacy
  • Additionally, in Oct 2018 Arrowhead collaborated with Janssen to develop and commercialize Arrowhead’s ARO-HBV
  • JNJ-3989 (SC) is an investigational antiviral liver-targeting candidate designed to treat chronic HBV infection via the ribonucleic acid interference (RNAi) mechanism. JNJ-6379 (PO) is capsid assembly modulator of the class that forms normal capsid structures (CAM-N)

Click here to read full press release/ article | Ref: Arrowhead Pharmaceuticals | Image: Bioworld

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post